Acute Myeloblastic Leukemia (AML)

Prof. Dr. Fevzi ALTUNTAS

Ankara Yıldırım Beyazıt Medical School

Department of Internal Medicine

Division of Hematology

Term-IV, 2020, Ankara

ACUTE LEUKEMIA

Acute Leukaemia

- Define :
  - Heterogeneous group of malignant disorders which is characterized by uncontrolled clonal and accumulation of blasts cells in the bone marrow and body tissues
- Sudden onset
- If left untreated is fatal within a few weeks or months
- Incidence 2-3/100,000

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukaemogenesis

- **Develop as a result of a genetic alteration within single cell in the bone marrow**
  - **a*)*** ***Epidemiological evidence :***
    - **1. Hereditary Factors**
      - **Fanconi's anaemia**
      - **Down's syndrome**
      - **Ataxia telangiectasia**
    - **2. Radiation, Chemicals and Drugs**
    - **3. Virus related Leukemias**
      - **Retrovirus : HTLV 1 & EBV**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukaemogenesis

b) Molecular Evidence

- ***Oncogenes* :**
  - Gene that code for proteins involved in cell proliferation or differentiation
- ***Tumour Suppressor Genes :***
  - Genes that protect a cell from one step on the path to cancer.
  - Genes that normally prevent cell division.
- **Changes within oncogene or suppressor genes are necessary to cause malignant transformation.**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukaemogenesis

Oncogene can be activated by:

1)chromosomal translocation


2)point mutations

3)inactivation

- In general, **several genes** have to be altered to effect neoplastic transformation.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukemia



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Pathophysiology

- Acute leukemia cause morbidity and mortality through:
  - **A. Deficiency in blood cell number and function**
  - **B. Invasion of vital organs**
  - **C. Systemic disturbances by metabolic imbalance**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Pathophysiology

A. Deficiency in blood cell number or function

i. Infection

- Most common cause of death
- Due to impairment of phagocytic function and neutropenia

ii. Hemorrhage

- Due to thrombocytopenia or 2^{o} DIC or liver disease

iii. Anemia

- Normochromic-normocytic
- Severity of anemia reflects severity of disease
- Due to ineffective erythropoiesis

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Pathophysiology

B. Invasion of vital organs

- Vary according to subtype

i. Hyperleukocytosis

- Cause increase in blood viscosity
- Predispose to microthrombi or acute bleeding
- Organ involve : brain, lung, eyes
- Injudicious used of packed cell transfusion precipitate hyperviscosity

ii. Leucostatic tumour

- Rare
- Blast cell lodge in vascular system forming macroscopic pseudotumour – erode vessel wall cause bleeding

iii. Hidden site relapse

- Testes and meninges (CNS)

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Pathophysiology

C. Metabolic imbalance

- Due to disease or treatment
  - Hyponatremia vasopressin-like subst. by myeloblast
  - Hypokalemia due to lysozyme release by myeloblast
  - Hyperuricaemia- spontaneous lysis of leukemic blast release purines into plasma
  - Tumor lysis syndrome- hyperkalemia, hyperphosphatemia, hypocalcaemia, hyperuricaemia

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Pathogenesis of tumor lysis syndrome



Mosby items and derived items © 2006 by Mosby, Inc.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Pathophysiology



Mosby items and derived items © 2006 by Mosby, Inc.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Classification



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Myeloid Leukemia (AML)

- Arise from the malignant transformation of a myeloid precursor
- Rare in childhood (10%-15%)
- The incidence increases with age
  - **80% in adults**



- **Auer rods** are pathognomonic for AML

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Myeloid Leukemia

Clinical manifestation:

- Gum hypertrophy (AML-M4/M5)
- Bone and joint pain
- Neurological symptoms: headache, nausea, vomiting, blurred vision, cranial nerve dysfunction (AML-M4/M5)
- DIC (APL; AML-M3)
- Skin deposit
- Renal damage



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Investigations

1. Complete blood count


- **Anemia**
  - **normochromic, normocytic**
- **WBC <1.0x10^9/l to >200x10^9/L,**
  - **Neutropenia and**
  - **full blast cells**
- **Thrombocytopenia <10x10^9/L.**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations



Acute lymphoblastic leukemia




Acute myeloblastic leukemia

Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations

- **ALL (Lymphoblast)**
  - **Blast size** : Small
  - **Cytoplasm**: Scant
  - **Chromatin**: Dense
  - **Nucleoli** : Indistinct
  - **Auer-rods**: Never present



- **AML (Myeloblast)**
  - Large
  - Moderate
  - Fine, Lacy
  - Prominent
  - **Present in 50%** (pathognomonic)

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations


2. Bone marrow aspiration

and trephine biopsy

- **confirm acute leukemia**

blast ≥ 20%

- **usually hypercellular**



Lymphoblast ≥25% - ALL (according to WHO)

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Classification according to Morphology

FAB	Common Name	Predominant Cell Type
M-0	Undifferentiated	Myeloblasts - no differentiation
M-1	Minimally differentiated	Myeloblasts - minimal differentiation
M-2	Myelocytic (-blastic)	Myeloblasts -with differentiation
M-3	Promyelocytic	Hypergranular promyelocytes
M-4	Myelomonocytic	Myelomonoblasts
M-5	Monocytic (-blastic)	Monoblasts
M-6	Erythroleukemia	Erythroblasts and Myeloblasts
M-7	Megakaryocytic	Megakaryoblasts

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Investigations

3. Cytochemical staining

a) Peroxidase (MPO):

   a) Negative ALL

   b) Positive AML




Positive for myeloblast

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations


b) Periodic acid schiff (PAS)
   - Positive ALL
   - Negative AML



Block positive in ALL

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

CYTOCHEMICAL CLASSIFICATION OF ACUTE LEUKEMIA



Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations

4. Immunophenotyping

- identify antigens **present on the blast cells**
- **determine whether the leukaemia is lymphoid or myeloid**
  - especially important when cytochemical markers are negative. E.g : AML-M0.
- has a **prognostic role**
  - Certain antigens have prognostic significance
- diagnose biphenotypic leukemia
  - both myeloid and lymphoid antigen are expressed on the same blast cells.
- identify the subtype of leukemia. E.g : AML-M7 has a specific surface marker of CD 61.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations

- Monoclonal antibodies (MoAb) are recognized under a cluster of differentiation (CD).

– **<u>MONOCLONAL ANTIBODIES USED FOR CHARACTERISATION OF AML.</u>**

AML : CD13, CD33

  - Erythroblast= CD71, Glycophorin-A $^{+}$
  - Monoblast= CD14, CD13, CD33^{+}
  - Megakaryoblast= CD41, CD42, CD61^{+}

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations

5. Cytogenetics and molecular studies

- detect abnormalities within the leukemic clone
- have diagnostic or prognostic value
  - E.g : the Philadelphia chromosome : the product of a translocation between chromosomes 9 and 22
    - very poor prognosis in ALL

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Investigations

COMMON CHROMOSOME ABNORMALITIES ASSOCIATED WITH ACUTE LEUKEMIA

- t(8;21) AML with maturation (M2)
- t(15;17) APL
- Inv 16 AML-M4eo

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Investigations



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Others Investigations

6. ***Biochemical screening***
   - **leucocyte count very high - renal impairment and hyperuricemia**
7. ***Lumbar puncture*** **(LP)**
   - **initial staging investigation to detect leukemic cells in the cerebrospinal fluid, indicating involvement of the CNS**
   - Done in AML-M4/5

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

2016 WHO classification of AML

Acute myeloid leukemia (AML) and related neoplasms

AML with recurrent genetic abnormalities

- AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
- AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
- APL with PML-RARA AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
- AML with t(6;9)(p23;q34.1);DEK-NUP214 AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
- AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
- Provisional entity: AML with BCR-ABL1 AML with mutated NPM1 AML with biallelic mutations of CEBPA
- Provisional entity: AML with mutated RUNX1

AML with myelodysplasia-related changes

Therapy-related myeloid neoplasms

AML, NOS

- AML with minimal differentiation
- AML without maturation
- AML with maturation
- Acute myelomonocytic leukemia
- Acute monoblastic/monocytic leukemia
- Pure erythroid leukemia
- Acute megakaryoblastic leukemia
- Acute basophilic leukemia
- Acute panmyelosis with myelofibrosis

Myeloid sarcoma

Myeloid proliferations related to Down syndrome


Transient abnormal myelopoiesis (TAM)
Myeloid leukemia associated with Down syndrome

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

AML: French-American-British(FAB) Classification

M0: with minimal differentiation

M1: without maturation



©ELSEVIER, INC. – ELSEVIERIMAGES.COM

M2: with maturation

M3: promyelocytic

M4: myelomonocytic

M5: monoblastic /monocytic

M6: erythroid

M7: megakaryoblastic

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


FAB vs WHO: Classifications of AML:

- **FAB criteria**
  - Morphology
  - Cytochemistry
- **WHO criteria**
  - Clinical features
  - Morphology
  - Immunophenotyping
  - Cytogenetic features

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Minimally differentiated AML (FAB-M0)


- 5% - 10% of AML
- Negative MPO
- Blasts are negative for B and T lymphoid antigens, platelet glycoproteins and erythroid glycophorin A
- Myeloid antigens : CD13, CD33 and CD11b are positive.



Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Myeloblastic without maturation (FAB-M1)

- 10 - 20% of AML
- **>90% cells are myeloblasts**
- >3% of blasts stain for MPO
- +8 frequently seen
- Myeloid antigens : CD13, CD33 are positive.



Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

AML with maturation (FAB-M2)

- **Most common AML**
  - 30 - 40% of AML
- 20% - 90% are myeloblasts
- MPO positive
- ~ 15% with t(8:21)



Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Frequency of AML subtype

Table I. Morphological types (M1-M7) in AML.

Types of AML	Number of patients	Percentage
*AML-MO	01	1.61
AML-M1	14	22.58
AML-M2	20	32.26
AML-M3	06	9.68
AML-M4	14	22.58
AML-M5	05	8.06
AML-M6	01	1.61
AML-M7	01	1.61


*One patient was labelled as AML-MO (not a FAB type).


M2 is the most common type of AML

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Promyelocytic Leukemia (FAB-M3)

- 10-15%
- marrow cells **hypergranul promeyelocytes**
  - **≥ 30% promyelosit**
- **Auer rods/ faggot cells** may be seen
- Classical type- Hypergranular, 80% **leukopaenic**
- Variant type- Hypogranular, leukocytosis
- Granules contain procoagulants (thromboplastin-like) - massive **DIC**
- **t(15:17) is diagnostic**
- **Best Prognosis**





Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

DIC and Acute Promyelocytic Leukemia

Pathogenesis of Coagulopathy in APL

Mechanism	Putative Mediators
DIC	Tissue factor
	Cancer procoagulant
	Cytokines (IL-1, TNF)
Fibrinolysis	tPA, uPA, PAI-1
	Annexin
Proteolysis	Elastases (targets include fibrinogen and vWF)

Abbreviations: IL-1, interleukin-1; PAI-1, plasminogen activator inhibitor-1; TNF, tumor necrosis factor; tPA, tissue-type plasminogen activator; uPA, urokinase; vWF, von Willebrand factor.

Mosby items and derived items © 2006 by Mosby, Inc.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

APL has the best prognosis






Figure 2. Disease free survival in patients affected by AML.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Myelomonocytic Leukemia (FAB-M4)

- 10-15%
- **Increased incidence CNS involvement**
- Monocytes and promonocytes 20% - 80%
- **Monocytosis (> 5.000/uL)**
- **NSE (esteraz)+**
- M4 with **eosinophilia (M4-Eo) associated with del/inv 16q**
  - marrow eosinophil from 6% - 35%







Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Acute Monoblastic Leukemia (FAB-M5)

M5a Acute Monoblastic Leukemia

- 10-15%
- Often assoc with **infiltration into gums/skin**
- Weakness, bleeding and diffuse erythematous skin rash
- MPO/SBB= negative,








Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Erythroleukemia (FAB-M6)

M6 Erythroleukemia (Di Guglielmo)

- <5%
- At least 80% immature erythroid precursors with ≥30% proerythroblasts
- and **≥20%** of the remaining nonerythroid cells are myeloblasts (if <20% then myelodysplasia)
- Glycophorin A ve CD71= +++



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Megakaryoblastic Leukemia (FAB-M7)

- <5%
- Associated with **fibrosis**
- confirm origin with platelet peroxidase + electron microscopy or MAb to vWF or glycoproteins (CD61)
- ≥ %50 megakaryocytes



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Prognostic Factors for AML

Risk category	Genetic abnormality
Favorable	• t(8;21)(q22;q22.1); RUNX1-RUNX1T1 • inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow† Biallelic mutated CEBPA
Intermediate	• Mutated NPM1 and FLT3-ITDhigh† • Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow† (without adverse-risk genetic lesions) t(9;11)(p21.3;q23.3); MLLT3-KMT2A‡ • Cytogenetic abnormalities not classified as favorable or adverse
Adverse	• t(6;9)(p23;q34.1); DEK-NUP214 t(v;11q23.3); KMT2A rearranged t(9;22)(q34.1;q11.2); BCR-ABL1 inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) • -5 or del(5q); -7; -17/abn(17p) • Complex karyotype, § monosomal karyotype • Wild-type NPM1 and FLT3-ITDhigh† • Mutated RUNX1* • Mutated ASXL1* • Mutated TP53

*These markers should not be used as an adverse prognostic marker if they co-occur with favorable-risk AML subtypes

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

AML Treatment

AML induction and consolidation therapies

Induction		Consolidation	
AML			
Ara-C	200 mg/m² IV as continuous infusion × 7 d	Ara-C[b]	3 g/m² q12h IV as 2- to 3-h infusion on days 1, 3, and 5; repeat q28d × 4 cycles
IDA[a]	12 mg/m² IV on days 1–3		
or			
Daun	60–90 mg/m² on days 1–3		
ALSG regimen			
Ara-C[b]	3 g/m² IV q12h as 2- to 3-h infusion on days 1, 3, 5, and 7 (8 doses)	Ara-C	100 mg/m² IV as continuous infusion × 5 d
Daun	45–60 mg/m² IV on days 1–3	Daun	50 mg/m² IV × 2 d
VP-16	75 mg/m² IV × 7 d	VP-16	75 mg/m² IV × 5 d


ALSG = Australian Leukemia Study Group; AML = acute myelogenous leukemia; Ara-C = cytarabine; Daun = daunorubicin; IDA = idarubicin; VP-16 = etoposide

[a] Idarubicin has been substituted for daunorubicin, 45 mg/m², which had been the prevalent anthracycline used in clinical trials prior to 1993. Mitoxantrone, 10 mg/m² × 5 days, has also been used as an alternative.

[b] For patients < 60 years of age

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Post Induction Therapy; AML 'transplant eligible' 1CR



Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

APL Treatment

ATRA treatment in APL



(A) Isomers of retinoic acid

(B) ATRA induces terminal differentiation of APL


(C) ATRA treatment leads to elimination of *PML-RARα*–positive cells by quantitative real-time RT-PCR for assessment of *PML-RARα* transcript.

Blood 2008 Mar 1;111(5):2505-15.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

APL Treatment

Recommended treatment algorithm for relapsed APL (ELN)



Allo = allogeneic; APL = acute promyelocytic leukemia; ATO = arsenic trioxide; ATRA = all-trans retinoic acid; Auto = autologous; chemo = chemotherapy; ELN = European LeukemiaNet; RT-PCR = reverse transcriptase-polymerase chain reaction; SCT = stem cell transplantation

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

www.drfevzialtuntas.com
faltuntas@hotmail.com

Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com